完全切除的IIB/C期黑色素瘤患者辅助纳武利尤单抗与安慰剂随机3期CheckMate 76 K试验的患者报告结局
在3期CheckMate 76 K试验中,辅助纳武利尤单抗较安慰剂显著改善切除后IIB/C期黑色素瘤的无复发生存和远处无转移生存。本文报告患者报告结局:至第53周健康相关生活质量两组无临床意义差异,纳武利尤单抗组严重副作用困扰比例低(1%-4%)。
要点
- EORTC QLQ-C30总体健康状况/生活质量的最小二乘均值差异为-1.3(95%CI:-2.9,0.4),无临床意义。
- EQ-5D-5L效用指数最小二乘均值差异为-0.011(95%CI:-0.025,0.004),VAS为-1.3(95%CI:-2.6,0.0)。
- 纳武利尤单抗组报告严重副作用困扰(「相当多」/「非常多」)的比例为1%-4%,安慰剂组为0%-2%。
核心结论
- 接受辅助纳武利尤单抗治疗的完全切除IIB/C期黑色素瘤患者健康相关生活质量稳定,副作用困扰轻微。
研究设计与样本
- 随机3期CheckMate 76 K试验(NCT04099251)的患者报告结局分析。
主要发现
- EORTC QLQ-C30各子量表(含总体健康状况/生活质量)从基线至第53周的变化在两组间无临床意义差异,总体健康状况/生活质量最小二乘均值差异为-1.3(95%CI:-2.9,0.4)。
- EQ-5D-5L效用指数最小二乘均值差异为-0.011(95%CI:-0.025,0.004),EQ-5D-5L VAS最小二乘均值差异为-1.3(95%CI:-2.6,0.0)。
- EORTC QLQ-C30总体健康状况/生活质量确认恶化时间(TTCD)的纳武利尤单抗对比安慰剂风险比为1.10(95%CI:0.88,1.36),EQ-5D-5L效用指数为1.10(95%CI:0.86,1.42);EQ-5D-5L VAS的TTCD安慰剂组更长(HR:1.92;95%CI:1.39,2.64)。
- 报告严重副作用困扰(「相当多」/「非常多」)的患者比例极低:纳武利尤单抗组为1%-4%,安慰剂组为0%-2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase 3 CheckMate 76 K trial, adjuvant nivolumab significantly improved recurrence-free survival and distant metastasis-free survival versus placebo in patients with resected stage IIB/C melanoma. We report patient-reported outcomes from CheckMate 76 K. METHODS: Change from baseline to week 53 in health-related quality of life (HRQoL), as measured using the EORTC QLQ-C30 and EQ-5D-5L utility index and visual analog scale (VAS), was compared between treatment groups using linear mixed-effect models. Time to confirmed deterioration (TTCD) in HRQoL was assessed using Cox regression. Bother from side effects, as measured by the FACIT-GP5, was descriptively compared between treatment groups. RESULTS: There were no clinically meaningful differences in change from baseline between treatment groups in EORTC QLQ-C30 subscales, including global health status (GHS)/quality of life (QoL; least squares mean [LSM] difference: -1.3; 95 % confidence interval [CI]: -2.9, 0.4), and EQ-5D-5L utility index (LSM difference: -0.011; 95 % CI: -0.025, 0.004) and VAS (LSM difference: -1.3; 95 % CI: -2.6, 0.0). There was no difference in TTCD for nivolumab versus placebo in EORTC QLQ-C30 GHS/QoL (hazard ratio [HR]: 1.10; 95 % CI: 0.88, 1.36) or EQ-5D-5L utility index (HR: 1.10; 95 % CI: 0.86, 1.42); however, TTCD in EQ-5D-5L VAS was longer with placebo (HR: 1.92; 95 % CI: 1.39, 2.64). Proportions of patients reporting severe side effect bother ("quite a bit"/"very much") were minimal (nivolumab: 1 %-4 %; placebo: 0 %-2 %). CONCLUSIONS: Patients with resected stage IIB/C melanoma treated with adjuvant nivolumab demonstrated stable HRQoL and minimal bother from side effects. CLINICAL TRIAL INFORMATION: NCT04099251.
引用
- Kirkwood JM, Mohr P, Hoeller C, et al. Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. Eur J Cancer. 2025. PMID: 40139004. doi:10.1016/j.ejca.2025.115371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。